Dec 29, 2025 • Stock Traders Daily
BULLISH
Avoiding Lag: Real-Time Signals in (ACLX) Movement
This article provides a real-time signal analysis for Arcellx Inc. (NASDAQ: ACLX), highlighting positive near-term sentiment with a potential to erode mid-term weakness within a long-term strength context. It presents AI-generated institutional trading strategies including position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis. The analysis indicates strong support in the near and long term, with a weaker signal in the mid-term.
Dec 23, 2025 • Nasdaq
SOMEWHAT-BULLISH
Wells Fargo Initiates Coverage of Arcellx (ACLX) with Overweight Recommendation
Wells Fargo has initiated coverage of Arcellx (ACLX) with an Overweight recommendation. Analysts predict a 77.03% upside with an average one-year price target of $115.39/share for Arcellx. Institutional ownership data shows significant holdings by Gilead Sciences, T. Rowe Price Investment Management, and other major firms.
Dec 23, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
Is Wells Fargo’s Anito-cel Endorsement Reframing the Investment Case for Arcellx (ACLX)?
Wells Fargo recently initiated coverage of Arcellx (ACLX) with an "overweight" rating, emphasizing its experimental CAR-T therapy, anito-cel, for multiple myeloma as a potential future treatment pillar. This endorsement validates anito-cel's importance and may influence investor perception, particularly given the risks associated with clinical and regulatory execution, manufacturing scale-up, and the company's profitability. The article highlights how this re-evaluates Arcellx's investment narrative, even as share prices have declined and fair value estimates vary widely among analysts.
Dec 22, 2025 • Sahm
SOMEWHAT-BULLISH
Is Wells Fargo’s Anito-cel Endorsement Reframing the Investment Case for Arcellx (ACLX)?
Wells Fargo initiated coverage on Arcellx with an overweight rating, emphasizing the potential of their CAR-T therapy, anito-cel, for multiple myeloma treatment. This endorsement validates anito-cel's significance and may influence investor perception despite the company's ongoing losses and share price decline. While scientific milestones remain unchanged, the focus is now on regulatory interactions and the planned 2026 launch, with differing opinions on Arcellx's fair value highlighting varying expectations for future execution and commercialization.
Dec 22, 2025 • MarketBeat
NEUTRAL
Voya Investment Management LLC Reduces Stock Holdings in Arcellx, Inc. $ACLX
Voya Investment Management LLC recently reduced its stake in Arcellx, Inc. (NASDAQ:ACLX) by 10.3% in the third quarter, selling over 28,000 shares. This reduction aligns with Arcellx's weak quarterly results, which missed both EPS and revenue estimates, alongside recent insider selling activity. Despite these factors, institutional ownership of Arcellx remains high at over 96%.
Dec 20, 2025 • MarketBeat
NEUTRAL
Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Moderate Buy" by Analysts
Arcellx, Inc. (NASDAQ:ACLX) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 12-month price target of $115.71. Despite missing Q3 earnings and revenue estimates, institutional investors have shown increased interest, with hedge funds and other institutions owning 96.03% of the stock. Insiders, however, sold 33,843 shares, reducing their ownership to 8.35%.